Pelabresib

N/A

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NamePelabresib
Drug Alias NameCPI-232CPI-0610CPI-267232DAK539DAK-539
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain-containing protein 4 inhibitorsBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain-containing protein 4Bromodomain and extra terminal domain protein
Therapy Area/IndicationsSolid tumoursSplenomegalyPrimary Myelofibrosis +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[31] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesConstellation Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovartis AgQuotient Sciences - Philadelphia LlcNovartis Pharma Ag +[5] 
Inactive CompaniesUniversity of Texas Southwestern Medical Center
Active IndicationsSolid tumoursSplenomegalyPrimary Myelofibrosis +[15] 
Inactive IndicationsPeripheral Nervous System NeoplasmsMultiple MyelomaLymphoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A